Gene therapy for autoimmune demyelinating disease of the central nervous system

Archivum Immunologiae et Therapiae Experimentalis

Volumn 47, Issue 1, 1999, Pages 33-36

  Mathisen, Peter M ^a   Tuohy, Vincent K ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Autoimmune disease; Cytokines; Gene therapy; Growth factors; Interleukin 10; Interleukin 4; Myelin

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 4;

DEMYELINATING DISEASE; GENE THERAPY; GENETICS; HUMAN; REVIEW;

DEMYELINATING AUTOIMMUNE DISEASES, CNS; GENE THERAPY; HUMAN; INTERLEUKIN-10; INTERLEUKIN-4; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0033302242     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. CHEN L. Z., HOCHWALK G. M., HUANG C. and THORBECKE G. J. (1998): Alleviation of experimental allergic encephalomyelitis (EAE) by TGF-β1 transfected MBP-specific T cells. FASEB J., 12, A308.
2. CRISI G. M., SANTAMBROGIO L., HOCHWALD G. M., SMITH S. R., CARLINO J. A. and THORBECKE G. J. (1995): Staphylococcal enterotoxin B and tumor necrosis factor-alpha-induced relapses of experimental allergic encephalomyelitis: protection by transforming growth factor-beta and interleukin-10. Eur. J. Immunol., 25, 3035-3040.
3. DUBOIS-DALCQ M. (1995): Regeneration of oligodendrocytes and myelin. Trends Neurosci., 18, 289-291.
4. HICKEY W. F., HSU B. L. and KIMURA H. (1991): T-lymphocyte entry into the central nervous system. J. Neurosci. Res., 28, 254-260.
5. IJICHI A., NOEL F., SAKUMA S., WEIL M. M. and TOFILON P. J. (1996): Ex vivo gene delivery of platelet-derived growth factor increases O-2A progenitors in adult. Gene Ther., 3, 389-395.
6. KRAMER R., ZHANG Y., GEHRMANN J., GOLD R., THOENEN H. and WEKERLE H. (1995): Gene transfer through the blood-nerve barrier: NGF-engineered neuritogenic T lymphocytes attenuate experimental autoimmune neuritis. Nature Med., 1, 1162-1166.
7. LININGTON C. (1998): Experimental animal models. In ZHANG J., HAFLER D., HOHLFELD R. and MILLER A. (eds.): Immunotherapy in neuroimmunologic diseases. Martin Dunitz, London, 11-28.
8. MATHISEN P. M. and TUOHY V. K. (1998): Gene therapy and the treatment of autoimmune disease. Immunol. Today, 19, 103-105.
9. MATHISEN P. M., YU M., JOHNSON J. M., DRAZBA J. A. and TUOHY V. K. (1997): Treatment of experimental autoimmune encephalomyelitis with genetically modified memory T. cells. J. Exp. Med., 186, 159-164.
10. MCMORRIS F. A. and MCKINNON E. D. (1996): Regulation of oligodendrocyte development and CNS myelination by growth factors: prospect for therapy of demyelinating disease. Brain Pathol., 6, 313-329.
11. MUELLER R., KRAHL T. and SARVETNICK N. (1996): Pancreatic expression of interleukin 4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice. J. Exp. Med., 184, 1093-1099.
12. SHAW M. K., LORENS J. B., DHAWAN A., DALCANTO R., TSE H. Y., TRAN A. B., BONPANE C., ESWARAN S. L., BROCKE S., SARVETNICK N., STEINMAN L., NOLAN G. P. and FATHMAN C. G. (1997): Local delivery of interleukin 4 retrovirus-transduced T lymphocytes ameliorates experimental autoimmune encephalomyelitis. J. Exp. Med., 185, 1711-1714.
13. STEINMAN L. (1996): Multiple sclerosis: a coordinated immunological attack against myelin the central nervous system. Cell, 85, 299-302.
14. TOURBAH A., LINNINGTON C., BACHELIN C., AVELLANA-ADALID V., WEKERLE H. and BARON-VAN EVERCOOREN A. (1997): Inflammation promotes survival and migration of the CG4 oligodendrocyte progenitors transpanted in the spinal cord of both inflammatory and demyelinated EAE rats. J. Neurosci. Res., 50, 853-861.
15. TUOHY V. K. and MATHISEN P. M. (1998): T cell design: Optimizing the therapeutic potential of autoreactive T cells by genetic modification. Res. Immunol., 149, 82-90.